Bull
$52.29
Scenario price
$15.170
+0.275 (+1.81%)At close
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.
Ultragenyx Pharmaceutical Inc (RARE) is a good buy right now due to its recent FDA approval of Fayuvi, which is expected to drive revenue growth, and the sale of a Priority Review Voucher for $210 million, providing non-dilutive capital. The current price of $15.48 is significantly below the raised analyst price target of $39, suggesting a potential upside of 166%. Additionally, the RSI of 61.305 indicates that the stock is in a healthy momentum range, which supports a buying opportunity. However, the company still faces risks, including a substantial year-to-date decline of 34.41% and a negative net income of $92 million in the latest quarter, which investors should consider before making a decision.
Evercore ISI
$18
2026-09-21
Evercore ISI
2026-09-21
Price Target
$18
Barclays
$35
2026-09-21
Barclays
2026-09-21
Price Target
$35
Morgan Stanley
$20
2026-09-18
Morgan Stanley
2026-09-18
Price Target
$20
Canaccord
$39
2026-09-18
Canaccord
2026-09-18
Price Target
$39
Cantor Fitzgerald
$39
2026-09-18
Cantor Fitzgerald
2026-09-18
Price Target
$39
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Ultragenyx Sells Rare Pediatric Disease PRV for $203 Million

Ultragenyx Sells Priority Review Voucher for $210 Million

Pomerantz Investigates Ultragenyx for Securities Fraud

FDA Grants Full Approval to Fayuvi for Rare Disease Treatment

Ultragenyx Receives FDA Approval, Price Target Raised to $39
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ultragenyx Pharmaceutical Inc (RARE) is a good buy right now due to its recent FDA approval of Fayuvi, which is expected to drive revenue growth, and the sale of a Priority Review Voucher for $210 million, providing non-dilutive capital. The current price of $15.48 is significantly below the raised analyst price target of $39, suggesting a potential upside of 166%. Additionally, the RSI of 61.305 indicates that the stock is in a healthy momentum range, which supports a buying opportunity. However, the company still faces risks, including a substantial year-to-date decline of 34.41% and a negative net income of $92 million in the latest quarter, which investors should consider before making a decision.
18 analysts cover RARE: 10 rate it Buy, 7 Hold and 1 Sell. The average price target is 61.65.

Most traders are looking for the next coin that will pump. I'm looking for something else. WHO IS BUYING THE DIPS? Because a green candle tells you what already happened. The reaction after the candle tells you whether the move has real strength. Look at the market right now: BTC is still the liquidity anchor. ETH is trying to regain momentum. SOL and XRP are fighting for attention. ZEC is showing extreme volatility. And names like QNT and HBAR have already shown what happens when liquidity suddenly rotates into a narrative. But here's where traders get trapped: A coin pumps 20–30%. Everyone notices. Everyone starts talking about it. Then late buyers enter. And the original buyers start taking profit. That is how a bullish chart can turn into a brutal trap. ━━━━━━━━━━━━━━ 🧠 HERE'S THE TEST I USE I don't care how big the breakout candle is. I want to see what happens NEXT. Breakout → pullback → buyers defend → higher low → continuation. That is a much healthier structure. But: Breakout → instant FOMO → volume disappears → support breaks. That's distribution risk. Same green candle. Completely different market structure. ━━━━━━━━━━━━━━ ₿ AND THIS IS WHY BTC MATTERS If BTC holds its major support while an altcoin is building higher lows, I'm interested. If BTC starts losing structure while an altcoin is already massively extended, I'm much more careful. Because when liquidity leaves the market: BTC usually reacts first. High-beta alts can react MUCH harder. That's where leverage becomes dangerous. ━━━━━━━━━━━━━━ 🔥 MY CURRENT WATCHLIST BTC — market direction ETH — relative strength SOL — high-beta momentum XRP — large-cap rotation ZEC — extreme volatility QNT / HBAR — momentum after major expansion But I'm NOT chasing the biggest green candle. I'm waiting for the market to prove that buyers are willing to defend the move. ━━━━━━━━━━━━━━ THE HARDEST SKILL IN TRADING ISN'T FINDING A COIN. IT'S KNOWING WHEN NOT TO CHASE IT. You don't need to catch every pump. You need to survive long enough to catch the setups that actually matter. ━━━━━━━━━━━━━━ 👇 ONE QUESTION: If you could trade ONLY ONE for the next 7 days: BTC ETH SOL XRP ZEC QNT HBAR Which one are you choosing — and WHY? Don't just drop the ticker. Give me your reason. I'll reply with the key level I'd be watching. $QNT $RARE $BTC
Show more
⚡ FUTURES MARKET ROTATION: TWO SIDES OF THE SAME MOVE QNT • SOON • ARX • BTW • GRASS | PHA • RARE • BR • Q • KMNO September 27, 2026 The latest Futures screen shows a sharp split in market momentum: some contracts are attracting aggressive upside participation, while others are experiencing rapid downside pressure. 🟢 FUTURES GAINERS QNTUSDT — +54.98% SOONUSDT — +35.30% ARXUSDT — +25.83% BTWUSDT — +20.83% GRASSUSDT — +19.69% QNT is clearly leading this snapshot, while SOON and ARX are also showing strong short-term expansion. When several contracts move together, it can indicate concentrated momentum rather than a broad market-wide trend. But strong percentage moves also deserve context. Fast expansion can bring higher volatility, wider intraday swings and rapid reversals, especially in leveraged markets. 🔴 FUTURES LOSERS PHAUSDT — -18.26% RAREUSDT — -15.24% BRUSDT — -13.58% QUSDT — -13.24% KMNOUSDT — -12.86% The downside list tells a different story. PHA is showing the largest decline in this snapshot, followed by RARE and BR. Q and KMNO are also under noticeable short-term pressure. 🧠 WHAT THIS ACTUALLY TELLS US The interesting part isn't simply which token is green or red. It's the speed of the rotation. When futures contracts experience large moves on both sides at the same time, traders should pay attention to: • Momentum persistence vs. sudden reversal • Volume confirmation • Open interest changes • Funding conditions • Liquidation activity • Whether spot markets confirm the futures move A large percentage change alone doesn't explain the underlying market structure. 📌 Key takeaway: This is a snapshot of short-term futures momentum, not a confirmation of a longer-term trend. The strongest-looking move can also become the most volatile one. ⚠️ Risk Disclaimer: This post is for educational and informational purposes only. Futures and leverage involve substantial risk, and rapid price movements can result in significant losses. Always conduct your own research and manage risk carefully. $BTC $RARE $SOONNEW
Show more

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.